Literature DB >> 11739062

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.

L S Schneider1, P N Tariot, C G Lyketsos, K S Dagerman, K L Davis, S Davis, J K Hsiao, D V Jeste, I R Katz, J T Olin, B G Pollock, P V Rabins, R A Rosenheck, G W Small, B Lebowitz, J A Lieberman.   

Abstract

The authors describe the development of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) protocol for Alzheimer disease (AD), a trial developed in collaboration with the National Institute of Mental Health (NIMH), assessing the effectiveness of atypical antipsychotics for psychosis and agitation occurring in AD outpatients. They provide an overview of the methodology utilized in the trial as well as the clinical-outcomes and effectiveness measures that were implemented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739062

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  57 in total

Review 1.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study.

Authors:  Toru Okura; Brenda L Plassman; David C Steffens; David J Llewellyn; Guy G Potter; Kenneth M Langa
Journal:  J Am Geriatr Soc       Date:  2010-01-26       Impact factor: 5.562

3.  Dynamic treatment regimes for managing chronic health conditions: a statistical perspective.

Authors:  Bibhas Chakraborty
Journal:  Am J Public Health       Date:  2010-11-18       Impact factor: 9.308

4.  Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS).

Authors:  Toru Okura; Kenneth M Langa
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Apr-Jun       Impact factor: 2.703

5.  Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.

Authors:  G Livingston; A E Walker; C L E Katona; C Cooper
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-26       Impact factor: 10.154

6.  A Generalization Error for Q-Learning.

Authors:  Susan A Murphy
Journal:  J Mach Learn Res       Date:  2005-07       Impact factor: 3.654

Review 7.  Enhancing validity in co-occurring disorders treatment research.

Authors:  Gregory J McHugo; Robert E Drake; Mary F Brunette; Haiyi Xie; Susan M Essock; Alan I Green
Journal:  Schizophr Bull       Date:  2006-07-18       Impact factor: 9.306

8.  Using engineering control principles to inform the design of adaptive interventions: a conceptual introduction.

Authors:  Daniel E Rivera; Michael D Pew; Linda M Collins
Journal:  Drug Alcohol Depend       Date:  2006-12-13       Impact factor: 4.492

9.  Beyond efficacy: the STAR*D trial.

Authors:  Thomas R Insel
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

10.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.